Last Updated on January 16, 2019 by Sultan Beardsley
LEAVE A COMMENT AND CLICK HERE TO SUBSCRIBE FOR MS ARTICLE ALERTS AND OUR NEWSLETTER!
Since our CNAT article on January 1, 2019, the stock has seen a healthy gain, validating part of our thesis argued in the initial piece of the drop being an overreaction. A multitude of articles in CNATs favor have since surfaced, showing a glimpse of investors confidence in their treatment. This in culmination with what is beginning to look like a biotech reversal, news coverage of the NASH topic (including CNAT leading to a 30% gain) and a potential overreaction to the recent data readout suggest a continuation of price increase until the stock finds an appropriate range leading up to the next data readouts. The next catalytic driver should be data from Encore- NF and the extension portion of encore pH which we predicted would be successful based on evidence in our previous article “A Closer Look At CNATS Failed Clinical Trial.”
MS Money Moves and it’s Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.